GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BetterLife Pharma Inc (XCNQ:BETR) » Definitions » Valuation Rank

BetterLife Pharma (XCNQ:BETR) Valuation Rank


View and export this data going back to 2017. Start your Free Trial

What is BetterLife Pharma Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

  1. Three factors:
    • Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
    • Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
    • Industry relative valuation
  2. Companies without enough data is not ranked
  3. Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.

BetterLife Pharma Valuation Rank Related Terms

Thank you for viewing the detailed overview of BetterLife Pharma's Valuation Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

BetterLife Pharma Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BetterLife Pharma Inc (XCNQ:BETR) » Definitions » Valuation Rank
Comparable Companies
TSXV:XRTX XCNQ:TRYP XCNQ:CHGX TSXV:HEM XCNQ:DRUG TSXV:RKV TSXV:RP TSX:APLI XCNQ:MESC XCNQ:GLOW OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX
Traded in Other Exchanges
BETRF:USA NPAU:Germany
Address
1275 West 6th Avenue, Suite 300, Vancouver, BC, CAN, V6H 1A6
Website
https://www.abetterlifepharma.com
BetterLife Pharma Inc a biotechnology company, engages in the development and commercialization of psychedelic products for the treatment of mental disorders in Canada, the United States, Australia, and the European Union. It is involved in refining and developing drug candidates from a set of complementary interferon-based technologies that have the potential to engage the immune system to fight virus infections, such as coronavirus disease and human papillomavirus, and/or to directly inhibit tumors to treat various types of cancer.
Executives
Steven Sangha 10% Security Holder
Ahmad Doroudian Director, Senior Officer
Robert Metcalfe Director
James Russell Starr Senior Officer